home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9408c.zip
/
M9480570.TXT
< prev
next >
Wrap
Text File
|
1994-08-20
|
2KB
|
35 lines
Document 0570
DOCN M9480570
TI Intravenous immune globulin in primary immunodeficiency.
DT 9410
AU Haeney M; Hope Hospital, University of Manchester School of Medicine,;
Salford, UK.
SO Clin Exp Immunol. 1994 Jul;97 Suppl 1:11-5. Unique Identifier : AIDSLINE
MED/94306760
AB The development of safe and effective intravenous preparations of immune
globulin (IVIG) represents a major advance in the treatment of patients
with severe antibody deficiencies. Such therapy is expensive, few trials
have been performed to compare one type of IVIG preparation with another
under equivalent conditions, and published studies have been of
relatively short duration. The overall consensus is that high-dose IVIG
(at least 400/mg/kg/month) is superior to lower doses and most
clinicians aim to maintain trough IgG levels above an arbitrary level of
5 g/l. Adverse reactions, usually mild, are common in antibody-deficient
patients during the first few infusions, but severe, anaphylactoid
reactions are extremely rare other than in patients with antibodies to
IgA. IVIG is not associated with transmission of human immunodeficiency
virus or hepatitis B, but there remains a small but definite risk of
transmission of non-A, non-B hepatitis, including hepatitis C.
Self-infusion of IVIG in the patient's home is a realistic alternative
to hospitalization. In the UK, guidelines for home therapy have been
approved by professional medical bodies and by the Department of Health.
Home therapy has proven to be both safe and cost-effective.
DE Great Britain Hepatitis C/TRANSMISSION Home Care Services Human
Immunoglobulins, Intravenous/ADMINISTRATION & DOSAGE/ADVERSE
EFFECTS/*THERAPEUTIC USE Immunologic Deficiency Syndromes/*THERAPY
Safety Self Administration JOURNAL ARTICLE REVIEW REVIEW, TUTORIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).